Cytyc ( CYTC), a manufacturer of clinical products that focus on women's health, said its second-quarter earnings rose 13.2% from the year-ago period, helped by strong growth in domestic surgical products and international business.

The company earned $31.7 million, or 27 cents a share, in the quarter, compared with $28 million, or 23 cents a share, a year ago. Adjusted for items, earnings were $35.5 million, or 29 cents a share in the most recent quarter. Analysts polled by Thomson First Call were expecting earnings of 26 cents a share.

Second-quarter revenue rose 19.9% from a year ago to $150.4 million.

Gross profit for the quarter rose 18.1% from a year ago to $117.3 million, however gross margin declined 119 basis points to 78%. Operating income rose 8.2% to $49.9 million, while operating margin dropped 358 basis points to 33.2%.

By segment, second-quarter revenue from domestic diagnostic products increased 9% from a year ago to $84.1 million, revenue from domestic surgical products rose 42% to $50 million and revenue from international segment climb 23% to $16.3 million.

Shares rose 67 cents Thursday to $24.58.

This story was created through a joint venture between TheStreet.com and IRIS.

More from Stocks

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

Trump, China Trade, Target and Las Vegas Casinos - 5 Things You Must Know

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

9 Stocks Goldman Sachs Thinks Will Blow Wall Street's Performance Away in 2019

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Quick Read: 3 Things for Investors to Know Before Wednesday's Trading Session

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Replay: Jim Cramer on the Markets, Oil, General Electric, Zillow and Micron

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around

Pegasystems Founder Explains Why He Has One of the Hottest Tech Stocks Around